Journal News

Journal of Lipid Research launches junior associate editors program

ASBMB Today Staff
April 1, 2019

This year, the Journal of Lipid Research welcomes its first cohort of junior associate editors.

Raymond Blind Raymond Blind
Vanderbilt University
School of Medicine
Research area: Nuclear lipid signaling and structure
Mentor: George Carman

Gissette Reyes-Sofer Gissette Reyes−Soffer
Columbia University
Irving Medical Center
Research area: Regulation and metabolism of Lipoprotein(a)
Mentor: Henry Ginsberg

Brandon Davies Brandon Davies
University of Iowa
Carver College of Medicine
Research area: Lipid metabolism in endothelial cells
Mentor: Stephen Young 

Rotonya Carr Rotonya Carr
University of Pennsylvania Perelman School of Medicine
Research area: Metabolism and lipid droplets in liver disease
Mentor: Nick Davidson

The four assistant professors, chosen from nominations made by the journal’s associate editors, are partnering with senior editors to learn how to manage the peer-review process.

“Engagement with the best and brightest young investigators in the lipid field is an investment in the future of JLR,” Co-Editor-in-Chief Kerry−Anne Rye said.

The new editors — two Ph.D.s and two M.D.s — already have accrued accolades and earned the community’s trust. Two are recipients of the JLR Junior Investigator Award. One won the Journal of Biological Chemistry/Herb Tabor Young Investigator Award. Another is on the Deuel Conference board.

Co-Editor-in-Chief Nicholas Davidson said the program’s mission is two-fold: “It’s demystifying the peer-review process and also teaching what we hope are going to be the next generation of full associate editors.”

The new editors are serving a two-year term from March 1, 2019, to Feb. 28, 2021.

They also will contribute a new type of article to the journal — commentaries on exciting lipid research published elsewhere.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
ASBMB Today Staff

This article was written by a member or members of the ASBMB Today staff.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Disease-linked mutations disrupt protein phase behavior
Journal News

Disease-linked mutations disrupt protein phase behavior

April 9, 2026

Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.

The dual role of asprosin in chronic fatty liver disease
Journal News

The dual role of asprosin in chronic fatty liver disease

April 8, 2026

Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.

Novel inhibitor targets RAS-driven cancers
Journal News

Novel inhibitor targets RAS-driven cancers

April 7, 2026

Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.

Catching tau in the act
Journal News

Catching tau in the act

April 2, 2026

Using a new proximity-labeling approach, researchers reveal how tangles of the brain-associated protein tau may disrupt RNA biology long before neurons die.

How copper delivery fuels bacterial respiration
Journal News

How copper delivery fuels bacterial respiration

April 1, 2026

Researchers identify the roles of several proteins in copper homeostasis in the aerobic bacterium Caulobacter vibrioides.

Revealing the glycoproteome of a cancer subtype
Journal News

Revealing the glycoproteome of a cancer subtype

March 31, 2026

Researchers mapped the glycoproteome of extrahepatic cholangiocarcinoma and compared it to intrahepatic tumors. Differences in sugar modifications and immune cell content suggest new biomarkers and guide development of targeted immunotherapies.